Paris, December 17, 2019 – WeHealthTM Digital Medicine, the eHealth division of the Servier Group, and Aiscreenings, a French start-up specialized in artificial intelligence related to the retina, announce the signature of a partnership for the codevelopment and distribution license of Olyatis™, designed to improve the screening of diabetic retinopathy.  

Diabetes represents a major challenge for public health worldwide. According to the World Health Organisation (WHO), the number of people with diabetes increased from 108 million in 1980 to 422 million in 2014. One of the most serious complications of diabetes is diabetic retinopathy, or lesions on the retina. Diabetic retinopathy is currently one of the major causes of visual impairment. According to the WHO, the entire population of patients with type 1 diabetes will suffer from diabetic retinopathy after 10 years with the disease and 33% of patients with type 2 diabetes after 20 years.[1] For the latter, a third will suffer from a potentially blinding retinopathy.

Olyatis™, co-developped by WeHealthTM Digital Medicine and Aiscreenings, aims to facilitate the screening and care of patients suffering from diabetic retinopathy. Easy-to-use and easily adapted to the patient pathway, Olyatis™ uses artificial intelligence technology to perform screenings: an image of the eye fundus, obtained via a fundus camera is uploaded onto the Olyatis™ platform which then assesses the presence of diabetic retinopathy in the patient.

“WeHealthTM Digital Medicine’s purpose is to develop innovative solutions in eHealth to improve patient care, facilitate the practice of health care professionals, and contribute to reducing health-related costs,” according to Dr David Guez, Executive Director, Innovation & Scouting of WeHealthTM Digital Medicine. “We are very happy and proud to be able to collaborate with Aiscreenings to provide health care professionals with a solution that aims to improve the screening of diabetic retinopathy in patients.”

“This partnership with WeHealthTM Digital Medicine is the recognition of Aiscreenings’ excellence in artificial intelligence research applied to medical fundus imaging. It also confirms aiVisionTM technological platform potential for diabetic retinopathy management and prevention” stated Arnaud Lambert, President of Aiscreenings. “Clearly, our platform has now become a global benchmark for care and support to millions of people with chronic diseases.”

This partnership brings to 5 the number of WeHealthTM Digital Medicine partnerships in the area of diabetes.

About WeHealth™ Digital Medicine

Launched in November 2016, WeHealthTM Digital Medicine, the eHealth division of Servier group, aims to improve the lives of patients and healthcare professionals through digital technology. WeHealthTM Digital Medicine offers innovative digital and connected solutions as well as services making the most of collected data, to ensure better individual patient monitoring and to better prevent and predict disease progression. In an open innovative approach, WeHealthTM Digital Medicine identifies the most promising startups in eHealth, in France and internationally, to co-develop solutions. In this way, WeHealthTM Digital Medicine contributes to the creation of a partner ecosystem to facilitate and accelerate the development, industrialization and distribution of innovations and to render them accessible to the greatest number.

For more information: https://www.wehealth-digitalmedicine.com/         

Follow WeHealthTM Digital Medicine on social media:

Press contacts:

Sonia Marques : sonia.marques@servier.com – Tel. +33 (0) 1 55 72 40 21 / +33 (0) 7 84 28 76 13

Jean-Clément Vergeau : jean-clement.vergeau@servier.com – Tel. +33 (0) 1 55 72 46 16 / + 33 (0) 6 79 56 75 96


About Aiscreenings 

Aiscreenings is an artificial intelligence driven population health enhancement specialist. Aiscreenings operates worldwide focusing on patient’s health improvement and targeting every individual specific needs at population scale. Aiscreenings uses the science of data to identify and predict pathologies, especially in retinal imaging. Its users are stakeholders involved in health improvement: patients, health payors – public or private, employers, government entities, pharmaceutical industry, communities, hospitals, doctors and carers. Aiscreenings provides specific and personalised approaches to individual’s health improvement and health costs reduction. Aiscreenings has industrialized its proprietary technology infrastructure and artificial intelligence algorithm production capabilities to serve customers over three continents. To learn more: https://www.aivision.health/  

Press contacts:

Presse : media@aivision.health – Tel. +33 (0) 6 88 28 44 32


[1] https://www.who.int/blindness/causes/priority/fr/index6.html